Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocyte Chooses CEO Successor

Executive Summary

Personalised therapy specialist Endocyte Inc. has appointed Mike Sherman president and CEO succeeding founding CEO Ron Ellis, who has resigned. Sherman has been the company’s chief financial officer since 2006, and took on the additional role of chief operating officer in 2014. Prior to this, he held a variety of executive roles, most recently as vice president of finance and strategic planning at Guidant Corporation.

You may also be interested in...



Coronavirus Update: Moderna Still Confident Of November Readout

The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.

Executives On The Move: New CEOs At NantKwest And Cogent Biosciences

New Chief Technology Officers named at Seres Therapeutics, ERYTech Pharma and Adicet Bio

Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance

Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.

Topics

UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel